

## University of Groningen

### Research Priorities in Atrial Fibrillation Screening A Report From a National Heart, Lung, and Blood Institute Virtual Workshop

Benjamin, Emelia J.; Go, Alan S.; Desvigne-Nickens, Patrice; Anderson, Christopher D.; Casadei, Barbara; Chen, Lin Y.; Crijns, Harry J. G. M.; Freedman, Ben; Hills, Mellanie True; Healey, Jeff S.

*Published in:*  
Circulation

*DOI:*  
[10.1161/CIRCULATIONAHA.120.047633](https://doi.org/10.1161/CIRCULATIONAHA.120.047633)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2021

[Link to publication in University of Groningen/UMCG research database](#)

#### *Citation for published version (APA):*

Benjamin, E. J., Go, A. S., Desvigne-Nickens, P., Anderson, C. D., Casadei, B., Chen, L. Y., Crijns, H. J. G. M., Freedman, B., Hills, M. T., Healey, J. S., Kamel, H., Kim, D-Y., Link, M. S., Lopes, R. D., Lubitz, S. A., McManus, D. D., Noseworthy, P. A., Perez, M., Piccini, J. P., ... Al-Khatib, S. M. (2021). Research Priorities in Atrial Fibrillation Screening A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. *Circulation*, 143(4), 372-388. <https://doi.org/10.1161/CIRCULATIONAHA.120.047633>

#### **Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

#### **Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# Research Priorities in Atrial Fibrillation Screening

## A Report From a National Heart, Lung, and Blood Institute Virtual Workshop

**ABSTRACT:** Clinically recognized atrial fibrillation (AF) is associated with higher risk of complications, including ischemic stroke, cognitive decline, heart failure, myocardial infarction, and death. It is increasingly recognized that AF frequently is undetected until complications such as stroke or heart failure occur. Hence, the public and clinicians have an intense interest in detecting AF earlier. However, the most appropriate strategies to detect undiagnosed AF (sometimes referred to as subclinical AF) and the prognostic and therapeutic implications of AF detected by screening are uncertain. Our report summarizes the National Heart, Lung, and Blood Institute's virtual workshop focused on identifying key research priorities related to AF screening. Global experts reviewed major knowledge gaps and identified critical research priorities in the following areas: (1) role of opportunistic screening; (2) AF as a risk factor, risk marker, or both; (3) relationship between AF burden detected with long-term monitoring and outcomes/treatments; (4) designs of potential randomized trials of systematic AF screening with clinically relevant outcomes; and (5) role of AF screening after ischemic stroke. Our report aims to inform and catalyze AF screening research that will advance innovative, resource-efficient, and clinically relevant studies in diverse populations to improve the diagnosis, management, and prognosis of patients with undiagnosed AF.

Emelia J. Benjamin<sup>1</sup>,  
MD, ScM

Sana M. Al-Khatib<sup>2</sup>, MD,  
MHS

With the aging of the population and improved survival with cardiovascular disease, the age-adjusted incidence and prevalence<sup>1</sup> and lifetime risk<sup>2</sup> of atrial fibrillation (AF) are increasing in the United States and globally.<sup>3</sup> The epidemic of AF has been accompanied by increased awareness of its complications, including ischemic stroke, cognitive impairment, dementia, heart failure, myocardial infarction, arterial and venous thromboembolism, chronic kidney disease, diminished quality of life, increased health care costs, and premature death.<sup>3</sup>

In 2009, the National Heart, Lung, and Blood Institute (NHLBI) identified research opportunities for the prevention of AF that were based on the proceedings of an NHLBI expert workshop.<sup>4</sup> A decade later, the NHLBI initiated a series of webinars bringing together international AF leaders to characterize ongoing research gaps and new opportunities to inform and accelerate future AF research. The novel webinar format was pursued by NHLBI to capture the expertise of global AF leaders in a resource-effective and timely fashion. The 2 workshops focused on AF ablation<sup>5</sup> and the bidirectional relations between AF and heart failure.<sup>6</sup> This article represents the

The full author list is available on page 384.

**Key Words:** atrial fibrillation  
■ diagnostic screening programs  
■ mobile health ■ prevention and control ■ research ■ stroke

© 2021 American Heart Association, Inc.

<https://www.ahajournals.org/journal/circ>

outcome of the third virtual workshop, held December 6, 2019, which focused on AF screening.

Using commercial and Medicare administrative claims databases, experts estimate that  $\approx 4.6$  million Americans have diagnosed AF, whereas  $\approx 700\,000$  (13%) have undiagnosed AF.<sup>7</sup> However, AF often is unrecognized clinically until the onset of complications. Simultaneously, AF is increasingly being detected by consumer-owned devices, with uncertain clinical implications. Hence, patients, clinicians, researchers, health systems and organizations, private and public payers, and governmental agencies have intense interest in delineating the optimal role of and approach to screening for AF. Numerous technologies can be used to screen individuals for AF, including the gold standard ECG, novel noncontact technologies,<sup>8</sup> noninvasive devices that detect pulse irregularity at a single time point, wearable devices such as smartwatches and patches, and implanted devices that monitor electrocardiographic rhythm long term.<sup>9</sup> The underlying premise of AF screening is that early detection will prompt management changes to potentially prevent progression and complications of AF.

There are many unanswered questions about the role of AF screening, uncertainty about the therapeutic implications of screen-detected AF, and concerns that AF screening may engender unwarranted testing, treatments, costs, and complications. The workshop covered the following topics related to AF screening: (1) role of opportunistic AF screening; (2) AF as a risk factor, risk marker, or both; (3) relations between AF burden detected with long-term monitoring and treatments/outcomes; (4) designs of potential randomized trials of systematic AF screening with clinically relevant outcomes; and (5) role of AF screening after ischemic stroke. The individual topic frameworks and recorded webinar will be posted on the NHLBI website simultaneously with the publication of this report. This document seeks to identify AF screening research opportunities that will be impactful, innovative, resource efficient, and clinically relevant with the ultimate goal of improving the detection, management, and prognosis of patients with undiagnosed AF.

## OPPORTUNISTIC SINGLE-TIME-POINT SCREENING FOR AF


### Background

Incidentally detected AF and opportunistic single-time-point screening (OppSTS) occur in usual clinical practice during in-person clinic visits made for reasons other than screening for AF. The distinction between incidentally detected AF and OppSTS is that OppSTS occurs when primary care providers are encouraged to systematically screen for AF during routine consultations by examining pulse palpation, auscultation, or blood pressure

checks in patients at heightened risk for AF (eg, patients  $\geq 65$  years of age); if pulse irregularity is detected, a follow-up ECG is obtained to confirm AF.<sup>10,11</sup> OppSTS was not considered screening by the US Preventive Services Task Force, which regarded OppSTS as prompted pulse taking.<sup>12</sup> OppSTS has been shown to be feasible in selected practice settings, may be cost-effective, and is recommended by a variety of professional societies and organizations (Figure 1).<sup>9,13–15</sup> Systematic screening occurs when a target population (individuals  $\geq 65$  years of age or with heart failure, etc) is requested to undergo screening for AF, which may involve single or intermittent testing or continuous recordings of variable duration. In 2018, the US Preventive Services Task Force concluded that current evidence was insufficient to recommend routine systematic electrocardiographic screening for AF and noted the need for additional randomized, controlled trials (RCTs) evaluating the benefits and harms of systematic AF screening compared with usual care.<sup>12</sup> Hence, an understanding of OppSTS is essential as a potential comparator for pragmatic RCTs of systematic screening.

The yield of OppSTS is highly variable, depending on age, multiple demographic and clinical factors, most of which are related to underlying risk of AF, and the OppSTS strategy and screening modality (Figure 1). OppSTS detects 1.4% of patients with previously unrecognized AF if the age criterion of  $\geq 65$  years is used, with higher results in men than in women (regardless of detection method, setting, or region).<sup>16</sup> In a meta-analysis of 19 single-time-point screening studies from around the world with electrocardiographic verification of the AF diagnosis, the number needed to screen to detect 1 person  $\geq 65$  years of age with a Class 1 recommendation for anticoagulation (throughout the document, anticoagulation refers to oral forms) was 83.<sup>16</sup>

Despite the higher incidence and prevalence of clinically detected AF in individuals of European ancestry,<sup>3</sup> a recent multiethnic systematic screening study (mean age, 74 years; 51% women) reported that AF detected by electrocardiographic patch, which screened continuously for 14 days, was similar across race/ethnic groups. AF detection was 7.1% in White individuals, 6.4% in Black individuals, 6.9% in Hispanic individuals, and 5.2% in Chinese individuals (versus White individuals, all  $P > 0.50$ ).<sup>17</sup> The rates were considerably higher than age- and sex-adjusted rates reported from a single-time-point AF screening meta-analysis of individuals  $\geq 65$  years of age ( $\geq 1.44\%$ ) and  $< 65$  years of age (0.41%), presumably because of the longer screening duration and higher screening intensity.<sup>16</sup> The similar detection rates with systematic AF screening provide support for the hypothesis that racial variation in clinical AF partially reflects ascertainment bias and motivates the critical need to ensure that screening studies include diverse patient populations. The call for greater



**Figure 1. Comparison of opportunistic single-time-point screening with systematic and consumer-led screening.**

Tradeoffs between screening intensity/atrial fibrillation (AF) yield and stroke risk of screen-detected AF along the screening intensity continuum are illustrated. BID indicates twice daily; BP, blood pressure; ICM, intracardiac monitor; PPG, Photoplethysmogram; and QID, 4 times a day.

inclusion of ethnic/racial minorities in AF patients is further supported by a study reporting the substantial underrepresentation and underreporting of racial and ethnic minorities in the clinical studies cited in current guidelines for AF.<sup>18</sup>


It has not been definitively proven that AF detected by OppSTS carries a risk of thromboembolism comparable to that of clinically recognized AF. However, given strong evidence from RCTs for net benefit of anticoagulation in patients with clinically recognized AF and other stroke risk factors, a placebo-controlled RCT of anticoagulation in OppSTS-detected AF may be challenging to perform. Thus, the prognosis of AF detected incidentally during a clinical encounter has been studied as a surrogate for OppSTS-detected AF. The prognosis of incidentally detected asymptomatic AF appears no different from or may be even worse than that of clinically detected AF with symptoms,<sup>19</sup> and the risk reduction observed with anticoagulation appears to be similar.<sup>20</sup> These data underlie the viewpoint supporting OppSTS now.<sup>11</sup> However, this viewpoint is tempered by several factors, including recognition that (1) the likelihood of detecting AF with OppSTS is heterogeneous; (2) those with AF detected have variable risk of stroke and other outcomes; (3) the accuracy of OppSTS varies by screening strategy and modality; (4) false-positive screening tests may carry particular risks of economic, medical (including bleeding), and quality of life consequences; and (5) strong evidence for the role of treatment such

as routinely recommended anticoagulation in improving outcomes in screen-detected AF is lacking.

## Knowledge Gaps

Randomized trials of OppSTS versus no screening to prevent stroke or death are lacking, and it is uncertain whether the prognosis of OppSTS-detected AF and the prognosis of clinically detected AF are the same. These questions can be answered by screening studies with appropriate inclusion criteria and enough follow-up time to ascertain end points for which clinical management may change if AF is detected (Figure 2). RCTs would be required to demonstrate that OppSTS has a net benefit compared with usual care. However, OppSTS is already part of routine high-quality clinical care in many settings, and the large sample size required and study expense would make enrollment in stand-alone trials of OppSTS challenging. Alternative approaches would be to direct resources toward systematic screening studies comparing greater screening intensity with usual OppSTS.<sup>21</sup> OppSTS studies also could be designed as pragmatic trials involving integrated health care delivery systems using cluster designs and electronic health record tools for cost-efficient outcome assessments.

Randomized trials of OppSTS might target individuals eligible for guideline-directed anticoagulant therapy to prevent stroke and death.<sup>15</sup> Given the paucity of screening data in racially/ethnically diverse individuals,



**Figure 2. Opportunistic single time point screening for atrial fibrillation (AF).**

Questions remain about screening test accuracy by methodology, how often to screen, harms from screening, and whether treating screen-detected AF has the same benefits as clinically detected AF. OAC indicates oral anticoagulant; Opp STS, opportunistic single-time-point screening; PAF, paroxysmal atrial fibrillation; and RCT, randomized, controlled trial.

it will be essential to ensure that screening studies include adequate numbers of individuals of non-European ancestry.

There is insufficient information on the relation of detection method (eg, manually checked pulse, pulse-based technologies, single-lead, multiple limb-lead ECG, or noncontact) to accuracy and prognosis. An additional area of uncertainty is the balance between screening-related benefits and potential adverse outcomes that may ensue from false-positive screening tests, including additional tests, additional procedures, and treatment-related complications (eg, bleeding and worse quality of life).

Other knowledge gaps relate to how the type of AF detected may affect outcomes. For instance, it is uncertain how stroke risk varies with the proportion of cases of AF detected by OppSTS that is persistent or the degree of AF burden in those with paroxysmal AF. In addition, the incremental annual detection rate of OppSTS in those previously undiagnosed with AF is unknown. Stratification by AF type in pertinent studies is needed to inform requirements for repeated OppSTS (until AF detection) versus more intensive screening strategies.

## Research Opportunities

1. Examine the outcomes of OppSTS-detected AF in ethnically/racially diverse studies such as pragmatic trials or prospective cohort studies

comparing carefully matched OppSTS-detected AF with clinically detected AF to generate knowledge about their relative prognoses.

2. Determine the proportion of OppSTS-detected AF that is persistent by conducting observational and administrative studies that examine extended monitoring and follow-up.
3. Study the impact of detection-method accuracy (including newer technologies) on beneficial health outcomes versus additional unnecessary tests and procedures and diminished quality of life. This research could include prospective comparative studies, pragmatic trials, and RCTs of different devices and screening strategies with stroke, mortality, and other clinically relevant end points in diverse populations.

## AF: RISK FACTOR, RISK MARKER, OR BOTH?

### Background

AF is a potent risk factor for cardioembolic stroke, mechanistically linked through reduced left atrial flow velocities and formation of thrombus, primarily in the left atrial appendage.<sup>22</sup> A higher burden of AF has been associated with increased ischemic stroke risk,<sup>23–25</sup> supporting a causal link between altered atrial hemodynamics induced by AF and thromboembolic risk. The AF burden–stroke



association, however, relies on secondary analyses that may be confounded by differences in the clinical risk profile of individuals with low versus high AF burden. Studies are ongoing to clarify whether treating AF early with rhythm control or upstream therapies prevents major adverse cardiovascular events, which would potentially enhance the justification to research AF screening strategies in individuals at intermediate or high estimated risk.<sup>26</sup>

Alternatively, AF may serve as a risk marker of stroke. Stroke risk factors overlap significantly with factors predicting the development of AF.<sup>27,28</sup> Lower left atrial flow velocities and stasis are related to stroke risk, as evaluated by the CHA<sub>2</sub>DS<sub>2</sub>-VASc score,<sup>29</sup> implying an interaction between risk and atrial hemodynamics. Moreover, current approaches to restore sinus rhythm do not eliminate stroke risk despite causing significant reductions in AF burden,<sup>30</sup> consistent with evidence that anticoagulation is also effective in preventing ischemic stroke in high-risk patients in sinus rhythm and without a history of AF.<sup>31</sup> Conversely, despite having a major impact on left atrial hemodynamics, AF does not increase stroke risk to a level that warrants anticoagulation in young patients with low CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>32</sup> In addition, stroke risk predicted with the CHA<sub>2</sub>DS<sub>2</sub>-VASc score is modulated by AF burden, with low risk upgraded by high AF burden and vice versa in some studies,<sup>24</sup> whereas other studies have reported that greater AF burden is linked to higher stroke and transient ischemic attack (TIA) risk independently of predicted risk using the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation Study) or CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>33</sup>

Mortality is higher in patients with stroke with AF than in individuals who have either AF or stroke, regardless of whether AF precedes or follows the stroke, suggesting a common pathway for both conditions.<sup>34</sup> Together with recent data showing that thromboembolic events may occur remotely from AF episodes,<sup>34,35</sup> these findings indicate that long-term exposure to the environmental and genetic risk factors that promote AF also may independently promote thromboembolic events.

A similar paradigm applies to other end points. For instance, heart failure is both a cause and a complication of AF.<sup>36</sup> Whereas restoration of sinus rhythm has been found to be beneficial in selected patients with heart failure with AF,<sup>37</sup> left ventricular energetics and perfusion are impaired even in patients with so-called lone AF and do not fully recover after successful ablation.<sup>38</sup> Similarly, a meta-analysis reported that AF was associated with increased risk of myocardial infarction (relative risk, 1.54 [95% CI, 1.28–1.85]),<sup>39</sup> and conversely, myocardial infarction is included in risk prediction models for AF (hazard ratio, 1.64 [95% CI, 1.38–1.96]).<sup>28</sup>


## Knowledge Gaps

Taking the existing evidence into consideration, it would seem logical to monitor heart rhythm periodically in

individuals at high risk for AF and, more specifically, in those individuals who would be expected to benefit most from anticoagulation and aggressive risk factor management if AF were diagnosed. An alternative approach would be to combine major adverse cardiovascular events (eg, stroke, heart failure) risk stratification with the probability of incident AF using ECG, imaging, blood biomarkers, and genetic/genomic markers (Figure 3). Management (eg, anticoagulation) decisions might be based on more precise risk assessment of both conditions rather than AF detection alone. The former approach is supported by data indicating, for example, a significant association between left atrial dilatation and the probability of detecting AF with implantable devices<sup>40</sup> and the predictive value of these and other parameters (eg, NT-proBNP [N-terminal pro-B-type natriuretic peptide] and left atrial function<sup>41</sup>) for stroke risk. These strategies, however, have not been systematically tested, nor has their respective cost-effectiveness been compared.

More sophisticated atrial and ventricular phenotyping could play an important role not only in refining stroke risk but also in risk stratification for predicting the development of heart failure and other outcomes in the presence of AF. Such modalities might include the detection of diffuse fibrosis (eg, by T1 mapping cardiovascular magnetic resonance imaging), the evaluation of myocardial metabolism and energetics (eg, by 31P magnetic resonance spectroscopy or hyperpolarized carbon-13 cardiovascular magnetic resonance imaging),<sup>38,42</sup> or the assessment of local inflammation by computed tomography.<sup>43</sup> In individuals in sinus rhythm, identification of early myocardial markers for risk of stroke and other AF-related complications such as heart failure may aid the selection of patients who would benefit from more intensive AF screening and potentially preventive therapies. A deeper knowledge of the myocardial and systemic substrates of AF may stimulate RCTs of new or repurposed agents.<sup>44</sup>

An emerging area of AF screening research involves artificial intelligence (AI) algorithms of electronic health records, electrocardiographic signals, imaging data (eg, echocardiographic, cardiovascular magnetic resonance), noncontact facial monitoring,<sup>8</sup> and biomarker/genomic data. A recent large-scale, but single-center, retrospective study demonstrated the feasibility of an AI-based electrocardiographic algorithm for detecting the likelihood of previous AF (by ECG) on the basis of sinus rhythm ECGs.<sup>45</sup> Machine learning could potentially enhance identification of future AF risk and associated complications.<sup>46–48</sup> For example, an AI model incorporating time-dependent serial prothrombin international normalized ratio times in the first 30 days of enrollment in the GARFIELD-AF registry (Global Anticoagulant Registry in the Field–Atrial Fibrillation) has been reported to predict major bleeding, stroke/systemic embolism, and



**Figure 3.** Both atrial fibrillation (AF) risk factors (left, some examples given) and health data, including sophisticated imaging and biomarker data, may distinguish individuals at low (green), intermediate (yellow), and high (red) risk, in terms of both incident (or recurrent) AF and major adverse cardiovascular and cerebrovascular events and conditions (MACCEs).

Both retrospective and prospective studies should compare risk prediction by standard models and artificial intelligence, taking the elements within upper main ellipse into account, including response to risk management, incident AF, and MACCEs. The strategy for prioritization of research would focus most efficiently on people with high risk of AF and MACCEs (upper potential screen threshold for research). BMI indicates body mass index; BNP, brain natriuretic peptide; DM, diabetes; EHR, electronic health record; HF, heart failure; HTN, hypertension; and VHD, valvular heart disease.

death more effectively than time in therapeutic international normalized ratio range.<sup>49</sup> However, many AI studies to date are not transparent, have not been externally validated,<sup>50</sup> and are susceptible to bias.<sup>51,52</sup> In addition, the advantage of AI algorithms over standard risk prediction models<sup>47</sup> and their implications for clinical decision making, including intensification of screening for AF or treatment decisions, remain uncertain. Furthermore, AI-derived noncontact monitoring raises potential privacy concerns. However, if validated and guided by equity and integrity, AI may advance AF screening research and improve the precision of AF care.

## Research Opportunities

1. Use large-scale longitudinal studies to generate data on systemic and myocardial (especially atrial myopathy) substrates of AF using ECG, echocardiography, cardiovascular magnetic resonance, computed tomography, and biomarkers (traditional, genetic, and omic) to demonstrate whether estimated risk of AF and AF-related complications (eg, major adverse cardiovascular and cerebrovascular events and conditions such as stroke, heart failure, and dementia) can be refined. Such data

will assist in prioritizing research in screening individuals with undiagnosed AF and research to discover novel therapeutic targets.

2. Investigate and validate AI algorithms and standard risk prediction models of cross-sectional and longitudinal data, including electronic health record, electrocardiographic, biomarker, genetic/omic, and imaging data, while adhering to privacy protections, transparency, diversity, equity, and inclusiveness. Priorities for research would test whether implementing or intensifying AF screening and predicting which patients with screen-detected AF will develop complications will result in net clinical benefit.

## BURDEN OF AF AND DETECTION OF AF WITH DIFFERENT TECHNOLOGIES

### Background

In AF, stroke risk stratification schema such as CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc, Framingham, and ATRIA were developed from populations of patients with clinically diagnosed AF without respect to AF burden (defined as total density or percent of time in AF) or duration. Over the past decade, there have been dramatic advances in diagnostic monitoring and detection of AF across a variety of implantable, noninvasive, and consumer-facing wearable devices, which have enabled near-continuous detection of short, often subclinical, arrhythmia episodes.<sup>53,54</sup> Population screening also has been proposed with these devices.<sup>9</sup>

In patients with cardiac implantable electronic devices (CIEDs), observational data have shown that atrial high-rate episodes (AHREs) as short as 6 minutes are associated with incident clinical AF and incident ischemic stroke.<sup>55</sup> There is, however, a risk gradient because higher risk of stroke is associated with longer AHREs, especially those  $\geq 24$  hours.<sup>23</sup> Studies from implantable and noninvasive devices have shown a stroke-risk gradient based on AF burden, AF duration, and cardiovascular risk factors.<sup>24,33</sup> However, earlier studies also have reported temporal dissociation between AF episodes and ischemic stroke events,<sup>34,35</sup> albeit a higher stroke risk in the 5 days after AF occurrence.<sup>35</sup> Temporal discontinuity data suggest that AF may be a marker of thrombogenic substrate and vascular risk, even during prolonged periods of sinus rhythm.

The accuracy of consumer devices used for the detection of AF also is uncertain. For instance, a recent meta-analysis of 10 studies noted that smartphone camera applications to detect AF had reasonably high sensitivity (94.2%), specificity (95.8%), and negative predictive value (99.8%). However, the authors reported that the included studies had methodological limitations and modest positive predictive values (20.5%-39.2%), even

when restricted to individuals  $\geq 65$  years with hypertension.<sup>56</sup> The authors concluded that, in asymptomatic individuals, the false-positive AF results exceeded the true-positive AF results.

The absence of RCT data anchored on AF burden thresholds that should prompt anticoagulation has led to large evidence gaps and substantial treatment variation related to anticoagulation.<sup>57,58</sup> RCTs are ongoing for CIEDs<sup>59-61</sup> and implantable loop recorders in higher-risk individuals  $\geq 70$  years of age (Danish LOOP [Atrial Fibrillation Detected by Continuous Loop Monitoring]; NCT02036450).<sup>62</sup> Nevertheless, evidence gaps are likely to remain for atrial arrhythmias detected from a range of medical and consumer-grade devices.<sup>63</sup>

### Knowledge Gaps

It is unknown whether the pathophysiology of stroke in patients with clinically diagnosed AF and that of subclinical AF (SCAF) or device-detected AHREs are the same and whether anticoagulation reduces stroke risk in patients with CIED-detected AHREs/SCAF (Table 1). It is unknown whether AF burden or the longest episode of AF better predicts AF-related complications. In addition, research is needed to establish the optimal thresholds for AHREs/SCAF burden and duration that merit anticoagulation and how such thresholds should vary depending on the extent of coexisting clinical stroke risk factors, other comorbidities, and bleeding risk.

The optimal frequency, intensity, and type of AF monitoring are not established. It is unknown which device is most cost-effective to screen for AF in different patient groups and whether clinical and cost-effective AF screening can be achieved with intermittent electrocardiographic (single- and 12-lead) snapshots. It is also undetermined how data from pacemakers, implantable cardioverter-defibrillators, implantable loop recorders, wearable devices, and noncontact approaches calibrate with each other for AF burden and risk of outcomes.

A major unanswered question is the balance between potential benefits and risks of consumer-driven screening. Consumers have increasing access to commercial devices that have the potential to diagnose AF early, offering the hope that AF progression and complications can be prevented. However, evidence is lacking in several areas, including which segments of the population to target for screening, whether early detection of AF prevents progression and complications, and what strategies could prevent AF progression and complications such as neurohormonal modulators, anti-inflammatory medications, antifibrosis therapies, and aggressive risk factor management.

In addition, there are major concerns about unintended consequences of consumer-driven screening. For instance, will individuals with previous paroxysmal AF be falsely reassured by the absence of detected AF



**Table 1. AF Burden Measurement in Diagnostic Devices, Clinical Evidence Based on AF Duration, and Knowledge Gaps and Opportunities**

Device	Context of AF identification	AF burden measurement	Duration of detected atrial arrhythmias	Expected incremental increase in risk of stroke	Type of evidence for benefit of oral anticoagulation
Insertable cardiac monitor	Continuous, programmable; device-detected AF	Yes	AT without AF	Lower	No data
Implantable pacemaker or defibrillator	Continuous, programmable; device-detected AF	Yes	Very short (<6 min)		No data
Patch-based ambulatory electrocardiographic monitor	5-14 d continuous	Yes	Subclinical Short (6 min–24 h)		Observational data; ARTESIA and NOAH-AFNet trials ongoing
Pulse and ECG-capable smartwatch	Opportunistic pulse checking; user-prompted ECG rhythm strip	No	Clinical Paroxysmal		Randomized trials
Portable smartphone-connected single or multichannel ECG	User-prompted ECG rhythm strip	No	Clinical Persistent (weeks/months)		Randomized trials
12-Lead ECG or telemetry rhythm strip	Clinical presentation	No	Clinical Permanent (months/years)	Higher	Randomized trials

AF indicates atrial fibrillation; ARTESIA, Apixaban for the Reduction of Thrombo-Embolicism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; AT, atrial tachycardia; and NOAH-AFNet, Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes Trial.

if devices are used intermittently? There are uncertainties about the potential for complications from treatment of falsely diagnosed AF or AF not destined to cause harm such as increased patient anxiety, downstream testing/treatment financial costs, and anticoagulation or rhythm control–related complications.<sup>12</sup> There are also nontrivial health system concerns such as unintended exacerbation of health care disparities and increased frontline clinician stress from managing growing volumes of consumer-detected findings in the absence of evidence-based algorithms for follow-up testing and treatment, creating uncertainty and potential liability.

## Research Opportunities

1. Investigate whether the pathophysiology of ischemic stroke in patients with clinically diagnosed AF is the same as that in individuals with device-detected AHREs/SCAF using various study designs (eg, registry, observational cohort), and test whether anticoagulation reduces the risk of stroke in patients with AF detected by implanted monitors, wearables, and consumer devices (RCTs).
2. With technologies that can screen heart rhythms for longer periods of time and detect shorter episodes of arrhythmia, assess the optimal AF burden or AF episode duration threshold for prompting specific treatments, including anticoagulation and risk factor treatment and lifestyle modification. Study how such thresholds should be modified in the setting of specific comorbidities (using data from RCTs, registries, post hoc analyses from RCTs) or screening device type used

(eg, noninvasive wearables, implantable loop recorders, CIEDs).

3. Rigorously study the patient-, clinician-, and health system–level consequences of patient-initiated screening with consumer devices to develop and assess implementation algorithms for downstream testing and management (implementation science, registries, electronic health record data analyses, and RCTs) and to eliminate health care disparities related to screening.

## RANDOMIZED STUDY OF SYSTEMATIC AF SCREENING WITH CLINICALLY RELEVANT OUTCOMES

### Background

The creation of population-based AF screening programs to prevent stroke is attractive because such programs fulfill most of the Wilson-Junger criteria for successful screening programs.<sup>64</sup> AF is prevalent, is clearly associated with stroke<sup>65</sup> and other adverse outcomes,<sup>66</sup> can be identified in a preclinical phase, and can be treated with anticoagulation, which is highly effective at preventing ischemic stroke.<sup>67</sup> However, prevention-oriented organizations have not uniformly endorsed AF screening,<sup>12,68</sup> given the lack of RCT evidence that AF screening prevents stroke and concern that false positives will lead to higher costs, downstream testing, and bleeding. Nevertheless, direct-to-consumer AF detection devices are becoming more widely used.<sup>69,70</sup>

Numerous studies have documented that a variety of technologies can detect AF in different populations;<sup>71–73</sup> however, extrapolation to the impact of AF detection

on stroke<sup>21</sup> and other adverse outcomes has not compelled the introduction of population-based screening.<sup>12</sup> Several large trials are underway (Table 1 in the Data Supplement). It is also recognized that a single screening strategy is unlikely to be suitable for every patient population, health care setting, or country.


Whereas the vast majority of AF-screening efforts have focused on AF detection to prevent stroke, the most common outcomes after AF are death and heart failure.<sup>74</sup> As mentioned, AF predisposes to a wide array of other outcomes,<sup>66</sup> including cognitive decline,<sup>75</sup> dementia,<sup>76</sup> chronic and end-stage kidney disease,<sup>77</sup> extracranial systemic emboli,<sup>78</sup> venous thromboembolism,<sup>79</sup> myocardial infarction,<sup>39</sup> heart failure,<sup>39,77</sup> sudden death,<sup>77</sup> lower quality of life,<sup>80</sup> physical disability,<sup>81</sup> higher health care costs,<sup>82</sup> hospitalizations,<sup>83</sup> and all-cause mortality.<sup>77</sup> Hence, there is a need to examine other end points in AF screening studies, particularly cardiovascular, cognitive, health system, and mortality outcomes. Similarly, there is a need to develop an evidence base of effective strategies to prevent nonstroke complications of AF.

## Knowledge Gaps

It is unclear whether population-based AF screening programs can prevent stroke and do so cost-effectively (Figure 4). It is also uncertain whether asymptomatic individuals with AF incidentally identified by implanted, wearable, or direct-to-consumer devices benefit from anticoagulation. Several knowledge gaps must be addressed before RCTs can attempt to answer these questions. For example, what population is optimal for AF screening? Both the prevalence of AF and the risk of

stroke increase with advancing age; thus, screening older populations (eg,  $\geq 65$  or  $\geq 75$  years) may be most resource effective. AF and stroke risks increase further in individuals with additional clinical risk factors or biomarkers; whether such factors should be considered in the selection of patients for screening should be examined. The best screening method also is uncertain. Single-time-point, reusable devices are inexpensive and may be cost-effective, particularly because they detect mostly persistent AF, which has a higher stroke risk. However, long-term ambulatory electrocardiographic monitoring is more sensitive and could also be cost-effective if its cost decreases. Algorithms to minimize false positives also will be essential. In addition, one must define the threshold of AF burden that is associated with stroke risk, particularly given the long-term monitoring capabilities of consumer devices. Finally, one must demonstrate that screen-detected AF leads to initiation of therapies that result in a reduction of stroke and other outcomes.

Several RCTs of AF screening are now ongoing or in development, totaling >300 000 patients (see Table 1 in the Data Supplement for examples of completed and ongoing studies). Given the mathematical and logistical challenges of translating AF detection into stroke prevention, the AF screening community and public will require RCT data to understand what components of screening strategies work best and to define which strategies work best in specific patients, settings, and countries. Ideally, data will be meta-analyzed across studies to enhance the ability to define subgroups of patients with AF who are most likely to benefit from screening.



**Figure 4.** Knowledge gaps and research opportunities to be addressed in randomized trials of screening for atrial fibrillation (AF).

ICD indicates implantable cardioverter-defibrillator; OAC, oral anticoagulant; and TIA, transient ischemic attack.

## Research Opportunities

1. Conduct large RCTs of AF screening strategies in diverse (eg, age, sex, race/ethnicity, urban/rural) at-risk populations of individuals to prevent stroke and other AF-associated outcomes, including major adverse cardiovascular events (heart failure, myocardial infarction, arterial and venous thromboembolism, sudden death), cognitive impairment/dementia, chronic kidney disease progression, health system resource use, and all-cause death, as well as downstream complications (eg, bleeding) and health system and process outcomes (eg, hospitalizations, time required to interpret screening tests, and follow-up testing).
2. Perform patient-level meta-analysis and meta-regression of similar RCTs from different health systems and countries examining stroke and other outcomes related to AF screening strategies, and identify specific subgroups of patients most likely to benefit from screening.
3. Assess health system and economic analyses of various population-based screening strategies through administrative and clinical databases.

## POSTSTROKE SCREENING FOR AF

### Background

This section focuses on poststroke screening for AF. A subsequent NHLBI workshop report addresses research priorities for risk stratification and stroke prevention in individuals with AF.

Previously undiagnosed clinical AF is frequently identified after acute stroke or TIA.<sup>84</sup> Up to 25% of patients with cryptogenic stroke may have AF detected, depending on patient characteristics, stroke type, and intensity of AF monitoring.<sup>85</sup> Intensive search for AF in the poststroke setting often reveals SCAF consisting of very short episodes<sup>86</sup> with unclear thromboembolic potential. Poststroke AF in a given patient may represent (1) preexisting AF that led to stroke, (2) new-onset AF that occurred because of the stroke itself,<sup>87</sup> (3) lagging thrombogenic atrial myopathy marker that led to stroke,<sup>88</sup> or (4) an incidental finding in a population with significant cardiovascular/stroke risk factors.<sup>89</sup> Regardless, in current practice, poststroke AF diagnosis usually changes treatment with initiation of long-term anticoagulation.<sup>90</sup> The detection of AF poststroke is important because recent RCTs do not support routine anticoagulation for secondary stroke prevention in the absence of known AF.<sup>91,92</sup>

Whereas electrocardiographic monitoring during hospitalization for stroke is common, more prolonged monitoring for poststroke AF, which significantly

increases the yield of AF detection over 72 hours<sup>93,94</sup> or beyond, is not widely implemented. To be resource efficient, intensive AF monitoring requires a refined patient population. Demographics, classic cardiovascular risk factor burden, stroke characteristics, signs of atrial myopathy<sup>95</sup> (including ECG, structural, hemodynamic changes, biomarkers),<sup>96–98</sup> and AF genetic risk scores<sup>99</sup> may guide patient selection for monitoring beyond 72 hours.

## Knowledge Gaps

Optimal methods for poststroke AF monitoring have yet to be defined (Figure 5). It is unknown whether anticoagulation driven by different AF monitoring strategies or other markers of atrial myopathy besides AF improves event-free survival (recurrent stroke/TIA/systemic embolism and dementia) and mortality.


The underlying pathophysiological mechanisms linking AF and stroke are also incompletely understood. Experimental and model systems to explore causal pathways and to define AF subtypes according to their pathological relation to stroke (ie, causal, bystander, AF induced by stroke, marker of atrial myopathy) are largely missing.

There is a lack of in-depth phenotyping of stroke cohorts with ECG and improved noninvasive imaging for the atrial-ventricular-vascular axis. Existing and new information from biomarkers, genetics, and other omics (eg, epigenomic, transcriptomic, proteomic, metabolomic, and microbiome) in relation to atrial myopathy as it applies to stroke has not been leveraged sufficiently. Clinical factors, stroke features, biomarkers, imaging variables, genetics, and omics to refine selection of poststroke patients/patients with TIA for more intensified AF screening also have not been sufficiently characterized.

From a clinical perspective, integrated care concepts<sup>100</sup> after stroke for internal medicine/cardiology workup during the index stroke hospitalization and after discharge in patients at high risk for AF to improve quality of life, cost, and outcomes are missing.

## Research Opportunities

1. Existing and new deeply phenotyped, diverse (age/sex/race/ethnicity/urban versus rural/region) cohorts should be examined to better characterize patients with AF after ischemic stroke to develop and validate poststroke incident AF prediction tools examining combinations of patient characteristics, stroke features, electrocardiographic, imaging, laboratory, omics, and genetic markers. In particular, the role of atrial myopathy (with or without ventricular remodeling and hemodynamic changes) in stroke risk and selection of



**Figure 5.** Questions to address in screening for atrial fibrillation (AF) in individuals who experience a new ischemic stroke in the absence of previously recognized AF.

It will be important to identify when, how, and whom to monitor after stroke. CVD indicates cardiovascular disease; ICM, intracardiac monitor; and QOL, quality of life.

patients for intensified poststroke AF monitoring requires investigation.

2. Observational and randomized studies of diverse populations should generate evidence on the effectiveness of post-ischemic stroke AF monitoring strategies and assessment and treatment of atrial myopathy independently of clinical AF diagnosis for improved outcomes, including stroke recurrence, heart failure, cognitive impairment, quality of life, disability, and mortality.
3. Optimal monitoring strategies after ischemic stroke need to be defined. Advances require investigations of the pathway to AF diagnosis (currently based on electrocardiographic tracing), implementation science to determine how to integrate optimal diagnostic methods in daily workflow in diverse populations, and study of shared decision making so that patients are engaged with the chosen approach. Besides classic monitoring techniques, external and implantable loop recorders and increasingly available wearables need to be investigated systematically and against gold standard approaches.

## CONCLUSIONS

Increasing awareness of the prevalence of undiagnosed AF, coupled with recognition that AF often is first diagnosed with the onset of complications, has stimulated enthusiasm for AF screening and an increase in the number of consumer products potentially

capable of diagnosing AF. However, there is a lack of robust evidence to determine the most appropriate patients to target for screening, which screening strategies and technologies to use in what context, and what additional testing and treatments to pursue with screen-detected AF.

Several themes emerged from the workshop to advance the field of AF screening. To develop a compelling evidence base, it is essential to generate and share data across studies (enabling pooled analyses and meta-analyses) and to pursue study designs including basic/mechanistic, administrative, health care/electronic medical records, registries, cohorts, pragmatic trials, and RCTs. Studies of AF screening need to examine AF burden, duration, and pattern in relation to multiple outcomes (eg, cardiac, brain, kidney, quality of life, costs, all-cause death), in addition to stroke and TIA. The role of AF screening needs to be investigated in various patient subgroups (eg, age, sex, race/ethnicity, urban/rural, and comorbidities), practice settings, and countries but will be most resource effective if focused on individuals for whom therapy may change if AF is diagnosed. Given the underrepresentation and underreporting of racial and ethnic minorities in AF studies,<sup>18</sup> it will be particularly important to ensure their adequate representation in AF screening studies. In particular, it will be vital to determine how AF prognosis and treatment vary by AF detection method (eg, incidental, noncontact/nonelectrocardiographic screening, routine electrocardiographic screening, consumer devices, extended clinical electrocardiographic monitoring, and



**Table 2. Prioritized Research Opportunities for AF Screening**

OppSTS for AF
Examine the outcomes of OppSTS-detected AF in ethnically/racially diverse studies such as pragmatic trials or prospective cohort studies comparing carefully matched OppSTS-detected AF with clinically detected AF to generate knowledge about their relative prognoses.
Determine the proportion of OppSTS-detected AF that is persistent by conducting observational and administrative studies that examine extended monitoring and follow-up.
Study the impact of detection method accuracy (including newer technologies) on beneficial health outcomes vs additional unnecessary tests and procedures and diminished quality of life. This research could include prospective comparative studies, pragmatic trials, and RCTs of different devices and screening strategies with stroke, mortality, and other clinically relevant end points in diverse populations.
AF: risk factor, risk marker, or both?
Use large-scale longitudinal studies to generate data on systemic and myocardial (especially atrial myopathy) substrates of AF using ECG, echocardiography, CMR, computed tomography, and biomarkers (traditional, genetic, and omic) to demonstrate whether estimated risk of AF and AF-related complications (eg, major adverse cardiovascular and cerebrovascular events and conditions such as stroke, heart failure, and dementia) can be refined. Such data will assist in prioritizing research in screening individuals with undiagnosed AF and research to discover novel therapeutic targets.
Investigate and validate AI algorithms and standard risk prediction models of cross-sectional and longitudinal data, including electronic health record, ECG, biomarker, genetic/omic, and imaging data, while adhering to privacy protections, transparency, diversity, equity, and inclusiveness. Priorities for research would test whether implementing or intensifying AF screening and predicting which patients with screen-detected AF will develop complications will result in net clinical benefit.
Burden of AF and detection of AF with different technologies
Investigate whether the pathophysiology of ischemic stroke in patients with clinically diagnosed AF is the same as that in individuals with device-detected AHREs/SCAF using various study designs (eg, registry, observational cohort) and test whether anticoagulation reduces the risk of stroke in patients with AF detected by implanted monitors, wearables, and consumer devices (RCT).
With technologies that can screen heart rhythms for longer periods of time and detect shorter episodes of arrhythmia, assess the optimal AF burden or AF episode duration threshold for prompting specific treatments, including anticoagulation and risk factor treatment and lifestyle modification. Study how such thresholds should be modified in the setting of specific comorbidities (using data from RCT, registries, post hoc analyses from RCTs) or screening device type used (eg, noninvasive wearables, implantable loop recorder, CIED).
Rigorously study the patient, clinician, and health system-level consequences of patient-initiated screening with consumer devices to develop and assess implementation algorithms for downstream testing and management (implementation science, registries, electronic health record data analyses, and RCTs) and to eliminate health care disparities related to screening.
Randomized study of systematic AF screening with clinically relevant outcomes
Conduct large RCTs of AF screening strategies in diverse (eg, age, sex, race/ethnicity, urban/rural) at-risk populations of individuals to prevent stroke and other AF-associated outcomes, including major adverse cardiovascular events (heart failure, myocardial infarction, arterial and venous thromboembolism, sudden death), cognitive impairment/dementia, chronic kidney disease progression, health system resource use, bleeding, and all-cause death, as well as downstream complications (eg, bleeding) and health system and process outcomes (eg, hospitalizations, time required to interpret screening tests, and follow-up testing).
Perform patient-level meta-analysis and meta-regression of similar RCTs from different health systems and countries examining stroke and other outcomes related to AF screening strategies and identify specific subgroups of patients most likely to benefit from screening.
Assess health system and economic analyses of various population-based screening strategies through administrative and clinical databases.
Poststroke screening for AF
Existing and new deeply phenotyped, diverse (age/sex/race/ethnicity/urban vs rural/region) cohorts should be examined to better characterize patients with AF after ischemic stroke to develop and validate poststroke incident AF prediction tools examining combinations of patient characteristics, stroke features, ECG, imaging, laboratory, omics, and genetic markers. In particular, the role of atrial myopathy (with/without ventricular remodeling and hemodynamic changes) in stroke risk and selection of patients for intensified poststroke AF monitoring requires investigation.
Observational and randomized studies of diverse populations should generate evidence of the effectiveness of postischemic stroke AF monitoring strategies and assessment and treatment of atrial myopathy independently of clinical AF diagnosis for improved outcomes, including stroke recurrence, heart failure, cognitive impairment, quality of life, disability, and mortality.
Optimal monitoring strategies after ischemic stroke need to be defined. Advances require investigations of the pathway to AF diagnosis (currently based on electrocardiographic tracing), implementation science to determine how to integrate optimal diagnostic methods in daily workflow in diverse populations, and study of shared decision making so that patients are engaged with the chosen approach. Besides classic monitoring techniques, external and implantable loop recorders and increasingly available wearables need to be investigated systematically and against gold standard approaches.

AF indicates atrial fibrillation; AHRE, atrial high-rate episode; AI, artificial intelligence; CIED, cardiac implantable electronic device; CMR, cardiac magnetic resonance; OppSTS, opportunistic single-time-point screening; RCT, randomized controlled trial; and SCAF, subclinical atrial fibrillation.

CIED), patient characteristics (eg, age, sex, race/ethnicity, and comorbidities), and AF risk markers (eg, atrial myopathy, electrocardiographic, imaging, biomarkers, omics, and genetic factors). Although AI algorithms hold great promise for refining patient selection for AF screening and prediction of outcomes in screen-detected AF, much more needs to be done to ensure that such algorithms are transparent, accurate, unbiased, and

validated and improve patient care in diverse patient populations. Finally, close attention will need to be paid to both the potential benefits and adverse outcomes of AF screening strategies on the patient (eg, anxiety, testing, treatment complications) and the health system (eg, disparities, costs, and clinician liability and fatigue) before widespread screening is recommended. The research gaps and opportunities outlined in the workshop



(Table 2) will, we hope, accelerate AF screening research to improve the diagnosis, management, and prognosis of patients with undiagnosed AF.

## ARTICLE INFORMATION

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.120.047633>.

## Authors

Emelia J. Benjamin<sup>1</sup>, MD, ScM; Alan S. Go<sup>2</sup>, MD; Patrice Desvigne-Nickens<sup>3</sup>, MD; Christopher D. Anderson<sup>4</sup>, MD, MMSc; Barbara Casadei<sup>5</sup>, MD, DPhil; Lin Y. Chen<sup>6</sup>, MD, MS; Harry J.G.M. Crijns<sup>7</sup>, MD, PhD; Ben Freedman<sup>8</sup>, MBBS, PhD; Mellanie True Hills<sup>9</sup>, BS; Jeff S. Healey<sup>10</sup>, MD, MSc; Hooman Kamel<sup>11</sup>, MD; Dong-Yun Kim<sup>12</sup>, PhD; Mark S. Link<sup>13</sup>, MD; Renato D. Lopes<sup>14</sup>, MD, MHS, PhD; Steven A. Lubitz<sup>15</sup>, MD, MPH; David D. McManus<sup>16</sup>, MD, ScM; Peter A. Noseworthy<sup>17</sup>, MD; Marco V. Perez<sup>18</sup>, MD; Jonathan P. Piccini<sup>19</sup>, MD, MHS; Renate B. Schnabel<sup>20</sup>, MD, MSc; Daniel E. Singer<sup>21</sup>, MD; Robert G. Tieleman<sup>22</sup>, MD, PhD; Mintu P. Turakhia<sup>23</sup>, MD, MAS; Isabelle C. Van Gelder<sup>24</sup>, MD, PhD; Lawton S. Cooper<sup>25</sup>, MD, MPH; Sana M. Al-Khatib<sup>26</sup>, MD, MHS

## Correspondence

Emelia J. Benjamin, MD, ScM, Boston University School of Medicine, Collamore 8, Cardiovascular Medicine, 72 E Concord St, Boston, MA 02118. Email [emelja@bu.edu](mailto:emelja@bu.edu)

## Affiliations

Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.). Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.). Division of Research, Kaiser Permanente Northern California, Oakland (A.S.G.). Departments of Epidemiology, Biostatistics, and Medicine, University of California, San Francisco (A.S.G.). Departments of Medicine, Health Research, and Policy (A.S.G.) and Center for Digital Health (M.P.T.), Stanford University, CA. Division of Cardiovascular Sciences (P.D.-N., L.S.C.) and Office of Biostatistics Research (D.-Y.K.), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Department of Neurology, Center for Genomic Medicine, and McCance Center for Brain Health, Massachusetts General Hospital, Boston (C.D.A.). Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, UK (B.C.). Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis (L.Y.C.). Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, the Netherlands (H.J.G.M.C.). Heart Research Institute, Charles Perkins Centre, and Concord Hospital Department of Cardiology, Concord Clinical School, University of Sydney, Australia (B.F.). StopAfib.org, American Foundation for Women's Health, Decatur, TX (M.T.H.). Population Health Research Institute, McMaster University, Hamilton, ON, Canada (J.S.H.). Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY (H.K.). Department of Medicine, Division of Cardiology, UT Southwestern Medical Center, Dallas, TX (M.S.L.). Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L., J.P.P., S.M.A.-K.). Cardiovascular Research Center and Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School, Boston (S.A.L.). Department of Medicine, Division of Cardiology, University of Massachusetts Medical School, Worcester (D.D.M.). Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (P.A.N.). Division of Cardiovascular Medicine, Stanford University Medical Center, CA (M.V.P.). Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany (R.B.S.). DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Germany (R.B.S.). Division of General Internal Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, (D.E.S.). Department of Cardiology, University of Groningen, University Medical Center Groningen, the Netherlands (I.C.V.G., R.G.T.). Department of Cardiology, Martini Hospital, Groningen, the Netherlands (R.G.T.). Veterans Affairs Palo Alto Health Care System, CA (M.P.T.).

## Acknowledgments

The authors thank their colleagues Michael J. Barry and C. Seth Landefeld for presenting the US Preventive Services Task Force perspective on screening

during the webinar and providing astute comments on the manuscript. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the NHLBI; the National Institutes of Health (NIH); the US Preventive Services Task Force; the US Department of Health and Human Services; or the Department of Veterans Affairs.

## Sources of Funding

Dr Benjamin receives research funding from US NIH, NHLBI grants R01HL128914, 2R01HL092577, R01HL141434 01A1, NIH National Institute of Aging grant R01AG066010, and American Heart Association 18SFRN34110082. Dr Go receives research funding from the US NIH, NHLBI grant R01HL142834, and National Institute of Diabetes and Digestive and Kidney Diseases R01DK103612. Dr Anderson receives research funding from NIH National Institute of Neurological Disorders and Stroke R01NS103924 and American Heart Association 18SFRN34250007. Dr Casadei is supported by program grants from the British Heart Foundation and by the National Institute for Health Research Oxford Biomedical Research Center. Dr Chen receives research funding from US NIH, NHLBI R01HL126637, and R01HL141288 and additional support from R01HL142599 and R01HL127659. Dr Crijns receives research support from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, CVON 2014-9: Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electric Remodeling, and Vascular Destabilisation in the Progression of AF (RACE V). Dr Van Gelder receives support from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, CVON 2014-9: Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electric Remodeling, and Vascular Destabilisation in the Progression of AF (RACE V). Dr Kamel receives research funding from NIH NHLBI R01HL144541 and National Institute of Neurological Disorders and Stroke R01NS097443. Dr Lubitz receives research funding from NHLBI grant R01HL139731 and American Heart Association 18SFRN34250007. Dr McManus receives support from US NIH, NHLBI grants R01HL126911, R01HL137734, R01HL137794, R01HL135219, R01HL136660, and U54HL143541. Dr Perez receives support from US NIH, NHLBI grant R01HL136390. Dr Piccini's time is supported by R01HL128595 from the NHLBI. Dr Schnabel receives funding from the European Union's Horizon 2020 Research and Innovation Program under grant agreement 847770 AFFECT-EU, the European Research Council under the European Union's Horizon 2020 Research and Innovation Program (grant agreement 648131), ERACoSysMed3 (031L0239), and German Center for Cardiovascular Research (DZHK e.V.; 8121710103). Dr Turakhia reports support from R01DK095024 from the National Institute of Diabetes and Digestive and Kidney Diseases and the American Heart Association.

## Disclosures

Dr Benjamin is an uncompensated member of the MyHeartLab Steering Committee, which is a principal investigator-initiated (Jeffrey Olgin, MD) research grant to University of California, San Francisco from Samsung. Dr Go has received a research grant through his institution from iRhythm Technologies. Dr Go is also a member of the Operations Committee and Steering Committee for the GUARD-AF Study (A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke; NCT04126486) sponsored by Bristol Myers Squibb and Pfizer. Dr Anderson receives sponsored research support from Massachusetts General Hospital and Bayer AG and has consulted for ApoPharma, Inc. Dr Casadei is supported by a personal chair. She receives in-kind support (in the form of free assays and electrocardiographic monitors) from Roche Diagnostics and iRhythm. Dr Crijns receives unrestricted grant support from Medtronic Trading NL BV. Dr Freedman reports grants to the institution, personal fees, and nonfinancial support from Bayer Pharma AG; grants to the institution and personal fees from BMS/Pfizer; and personal fees from Daiichi-Sankyo and Omron. Dr van Gelder reports unrestricted grant support from Medtronic Trading NL BV. Dr Healy reports research grants and speaking fees from Medtronic, Boston Scientific, Abbott, BMS/Pfizer, Servier, Cipher Pharma, and ARCA Biopharm. Dr Healy also is supported by the Stuart Connolly Chair in Cardiology Research, McMaster University. Dr Kamel serves as co-principal investigator for the NIH-funded ARCADIA trial (Antithrombotic Drugs in Prevention After Cryptogenic Stroke), which receives in-kind study drug from the BMS-Pfizer alliance and in-kind study assays from Roche Diagnostics; serves as a steering committee member of Medtronic's Stroke AF trial (uncompensated); serves on an end point adjudication committee for a trial of empagliflozin for Boehringer-Ingelheim; and has served on an advisory board for Roivant Sciences related to factor XI inhibition. Dr Lopes reported research grants and personal fees from Bristol-Myers Squibb and Pfizer; personal fees from Boehringer Ingelheim and Bayer

AG; and grants from Amgen Inc, GlaxoSmithKline, Medtronic PLC, and Sanofi Aventis. Dr Lopes is also a member of the Operations Committee and Steering Committee for the GUARD-AF Study (NCT04126486) sponsored by Bristol Myers Squibb and Pfizer. Dr Lubitz receives sponsored research support from Bristol Myers Squibb/Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit; has consulted for Bristol Myers Squibb/Pfizer and Bayer AG; and participates in a research collaboration with IBM. Dr McManus has received research support from Bristol Myers Squibb, Care Evolution, Samsung, Apple Computer, Pfizer, Biotronik, Boehringer Ingelheim, Philips Research Institute, FLEXcon, and Fitbit and has consulted for Bristol Myers Squibb, Pfizer, Philips, Samsung Electronics, Fitbit, Rose Consulting, Boston Biomedical Associates, and FLEXcon. Dr McManus is also a member of the Operations Committee and Steering Committee for the GUARD-AF Study (NCT04126486) sponsored by Bristol Myers Squibb and Pfizer and the Steering Committee of the Fitbit Heart Study (NCT04380415). Dr Perez is co-principal investigator of the Apple Heart Study funded by Apple Inc; Dr Perez has received consulting fees from Apple Inc and Boehringer Ingelheim. Dr Piccini receives grants for clinical research from Abbott, Association for the Advancement of Medical Instrumentation, Bayer, Boston Scientific, and Philips and serves as a consultant to Abbott, Allergan, ARCA Biopharma, Biotronik, Boston Scientific, LivaNova, Medtronic, Milestone, Myokardia, Sanofi, Philips, and Up-to-Date. Dr Schnabel reports speaking fees from Bristol-Myers Squibb/Pfizer. Dr Singer reports research support from Bristol-Myers Squibb and steering committee/advisory board/consulting for Boehringer Ingelheim, Bristol-Myers Squibb, Fitbit, Johnson & Johnson, Merck, and Pfizer. Dr Tieleman reports grants and speaking fees from Boehringer Ingelheim, speaking fees from BMS/Pfizer, speaking fees from Bayer, grants from Medtronic, and grants from St. Jude Medical. In addition, Dr Tieleman has a patent as a coinventor of the MyDiagnostick issued. Dr Turakhia reports grants from Bristol Myers Squibb, Apple, Janssen, Boehringer-Ingelheim, American Heart Association, Medtronic, and Bayer; consulting fees from Medtronic, Myokardia, Biotronik, Pfizer, and Johnson & Johnson; and royalties from Up-to-Date. Dr Turakhia is an editor for *JAMA Cardiology*. Dr Turakhia is also a member of the Executive Committee for the HEARTLINE Study sponsored by Janssen Inc. Dr Al-Khatib reports consulting fees from Milestone Pharmaceuticals; research, speaking, and consulting fees from Medtronic; research and speaking fees from Abbott; and speaking fees from Bristol-Myers Squibb/Pfizer.

## Supplemental Materials

Data Supplement Table I  
References 101–122

## REFERENCES

- Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al. 50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet*. 2015;386:154–162. doi: 10.1016/S0140-6736(14)61774-8
- Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, McManus DD, Ko D, Weng LC, Lunetta KL, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. *BMJ*. 2018;361:k1453. doi: 10.1136/bmj.k1453
- Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. *Circulation*. 2020;141:e139–e596. doi: 10.1161/CIR.0000000000000757
- Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, et al. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. *Circulation*. 2009;119:606–618. doi: 10.1161/CIRCULATIONAHA.108.825380
- Al-Khatib SM, Benjamin EJ, Buxton AE, Calkins H, Chung MK, Curtis AB, Desvigne-Nickens P, Jais P, Packer DL, Piccini JP, et al. Research needs and priorities for catheter ablation of atrial fibrillation: a report from a National Heart, Lung, and Blood Institute Virtual Workshop. *Circulation*. 2020;141:482–492. doi: 10.1161/CIRCULATIONAHA.119.042706
- Al-Khatib SM, Benjamin EJ, Albert CM, Alonso A, Chauhan C, Chen PS, Curtis AB, Desvigne-Nickens P, Ho JE, Lam CSP, et al. Advancing research on the complex interrelations between atrial fibrillation and heart failure: a report from a US National Heart, Lung, and Blood Institute virtual workshop. *Circulation*. 2020;141:1915–1926. doi: 10.1161/CIRCULATIONAHA.119.045204
- Turakhia MP, Shafrin J, Bognar K, Trocio J, Abdulsattar Y, Wiederkehr D, Goldman DP. Estimated prevalence of undiagnosed atrial fibrillation in the United States. *PLoS One*. 2018;13:e0195088. doi: 10.1371/journal.pone.0195088
- Yan BP, Lai WHS, Chan CKY, Au ACK, Freedman B, Poh YC, Poh MZ. High-throughput, contact-free detection of atrial fibrillation from video with deep learning. *JAMA Cardiol*. 2020;5:105–107. doi: 10.1001/jamacardio.2019.4004
- Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, Albert CM, Anderson CS, Antoniou S, Benjamin EJ, et al; AF-Screen Collaborators. Screening for atrial fibrillation: a report of the AF-SCREEN international collaboration. *Circulation*. 2017;135:1851–1867. doi: 10.1161/CIRCULATIONAHA.116.026693
- Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, Raftery JP, Bryan S, Davies M, Lip GY, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. *BMJ*. 2007;335:383. doi: 10.1136/bmj.39280.660567.55
- Freedman B, Schnabel R, Calkins H. Opportunistic electrocardiogram screening for atrial fibrillation to prevent stroke. *JAMA Cardiol*. 2019;4:91–92. doi: 10.1001/jamacardio.2018.4335
- Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Kubik M, et al. Screening for atrial fibrillation with electrocardiography: US Preventive Services Task Force recommendation statement. *JAMA*. 2018;320:478–484. doi: 10.1001/jama.2018.10321
- Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, Banerjee A, Gorenk B, Brachmann J, Varma N, et al; ESC Scientific Document Group. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiología (SOLAECE). *Europace*. 2017;19:1589–1623. doi: 10.1093/europace/eux177
- Briege D, Amerena J, Attia JR, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani HM, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. *Med J Aust*. 2018;209:356–362. doi: 10.5694/mja18.00646
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37:2893–2962. doi: 10.1093/eurheartj/ehw210
- Lowres N, Olivier J, Chao TF, Chen SA, Chen Y, Diederichsen A, Fitzmaurice DA, Gomez-Doblas JJ, Harbison J, Healey JS, et al. Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. *PLoS Med*. 2019;16:e1002903. doi: 10.1371/journal.pmed.1002903
- Heckbert SR, Austin TR, Jensen PN, Chen LY, Post WS, Floyd JS, Soliman EZ, Kronmal RA, Psaty BM. Differences by race/ethnicity in the prevalence of clinically detected and monitor-detected atrial fibrillation: MESA. *Circ Arrhythm Electrophysiol*. 2020;13:e007698. doi: 10.1161/CIRCEP.119.007698
- Saraju A, Maron DJ, Rodriguez F. Under-reporting and under-representation of racial/ethnic minorities in major atrial fibrillation clinical trials. *JACC Clin Electrophysiol*. 2020;6:739–741. doi: 10.1016/j.jacep.2020.03.001
- Siontis KC, Gersh BJ, Killian JM, Noseworthy PA, McCabe P, Weston SA, Roger VL, Chamberlain AM. Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: characteristics and prognostic implications. *Heart Rhythm*. 2016;13:1418–1424. doi: 10.1016/j.hrthm.2016.03.003
- Freedman B, Martinez C, Katholing A, Rietbrock S. Residual risk of stroke and death in anticoagulant-treated patients with atrial fibrillation. *JAMA Cardiol*. 2016;1:366–368. doi: 10.1001/jamacardio.2016.0393
- Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: the STROKESTOP study. *Circulation*. 2015;131:2176–2184. doi: 10.1161/CIRCULATIONAHA.114.014343
- Zabaloitza M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation: Stroke Prevention in Atrial Fibrillation III Investigators. *J Am Coll Cardiol*. 1998;31:1622–1626. doi: 10.1016/S0735-1097(98)00146-6

23. Van Gelder IC, Healey JS, Crijns HJGM, Wang J, Hohnloser SH, Gold MR, Capucci A, Lau CP, Morillo CA, Hobbelt AH, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. *Eur Heart J*. 2017;38:1339–1344. doi: 10.1093/eurheartj/ehx042
24. Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS. Stroke risk as a function of atrial fibrillation duration and CHA<sub>2</sub>DS<sub>2</sub>-VASc score. *Circulation*. 2019;140:1639–1646. doi: 10.1161/CIRCULATIONAHA.119.041303
25. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, Ezekowitz J, Alings M, Yang H, Alexander JH, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. *Eur Heart J*. 2013;34:2464–2471. doi: 10.1093/eurheartj/ehf135
26. Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P, Wegscheider K. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. *Am Heart J*. 2013;166:442–448. doi: 10.1016/j.ahj.2013.05.015
27. Pisters R, Crijns HJ. Atrial fibrillation: a risk score for AF: burning the haystack to find the needle. *Nat Rev Cardiol*. 2009;6:394–395. doi: 10.1038/nrcardio.2009.74
28. Alonso A, Krijthe BP, Aspelund T, Stepan KA, Pencina MJ, Moser CB, Sinner MF, Sotoodehnia N, Fontes JD, Janssens AC, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. *J Am Heart Assoc*. 2013;2:e000102. doi: 10.1161/JAHA.112.000102
29. Markl M, Lee DC, Furiase N, Carr M, Foucar C, Ng J, Carr J, Goldberger JJ. Left atrial and left atrial appendage 4D blood flow dynamics in atrial fibrillation. *Circ Cardiovasc Imaging*. 2016;9:e004984. doi: 10.1161/CIRCIMAGING.116.004984
30. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah B, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. *Ann Intern Med*. 2014;160:760–773. doi: 10.7326/M13-1467
31. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. *N Engl J Med*. 2017;377:1319–1330. doi: 10.1056/NEJMoa1709118
32. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellnor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. *Circulation*. 2019;140:e125–e151. doi: 10.1161/CIR.0000000000000665
33. Go AS, Reynolds K, Yang J, Gupta N, Lenane J, Sung SH, Harrison TN, Liu TI, Solomon MD. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM study. *JAMA Cardiol*. 2018;3:601–608. doi: 10.1001/jamacardio.2018.1176
34. Camen S, Ojeda FM, Niiranen T, Gianfagna F, Vishram-Nielsen JK, Costanzo S, Söderberg S, Vartiainen E, Donati MB, Löchen ML, et al. Temporal relations between atrial fibrillation and ischaemic stroke and their prognostic impact on mortality. *Europace*. 2020;22:522–529. doi: 10.1093/europace/eu3212
35. Turakhia MP, Ziegler PD, Schmitt SK, Chang Y, Fan J, Than CT, Keung EK, Singer DE. Atrial fibrillation burden and short-term risk of stroke: case-crossover analysis of continuously recorded heart rhythm from cardiac electronic implanted devices. *Circ Arrhythm Electrophysiol*. 2015;8:1040–1047. doi: 10.1161/CIRCEP.114.003057
36. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. *Circulation*. 2003;107:2920–2925. doi: 10.1161/01.CIR.0000072767.89944.6E
37. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, et al; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med*. 2018;378:417–427. doi: 10.1056/NEJMoa1707855
38. Wijesurendra RS, Liu A, Eichhorn C, Ariga R, Levelt E, Clarke WT, Rodgers CT, Karamitsos TD, Bashir Y, Ginks M, et al. Lone atrial fibrillation is associated with impaired left ventricular energetics that persists despite successful catheter ablation. *Circulation*. 2016;134:1068–1081. doi: 10.1161/CIRCULATIONAHA.116.022931
39. Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2017;24:1555–1566. doi: 10.1177/2047487317715769
40. Healey JS, Alings M, Ha A, Leong-Sit P, Birnie DH, de Graaf JJ, Freericks M, Verma A, Wang J, Leong D, et al; ASSERT-II Investigators. Subclinical atrial fibrillation in older patients. *Circulation*. 2017;136:1276–1283. doi: 10.1161/CIRCULATIONAHA.117.028845
41. Habibi M, Zareian M, Ambale Venkatesh B, Samiei S, Imai M, Wu C, Launer LJ, Shea S, Gottesman RF, Heckbert SR, et al. Left atrial mechanical function and incident ischemic cerebrovascular events independent of AF: insights from the MESA study. *JACC Cardiovasc Imaging*. 2019;12:2417–2427. doi: 10.1016/j.jcmg.2019.02.021
42. Schroeder M, Laustsen C. Imaging oxygen metabolism with hyperpolarized magnetic resonance: a novel approach for the examination of cardiac and renal function. *Biosci Rep*. 2017;37. doi: 10.1042/BSR20160186
43. Watanabe E, Miyagawa M, Uetani T, Kinoshita M, Kitazawa R, Kurata M, Ishimura H, Matsuda T, Tanabe Y, Kido T, et al. Positron emission tomography/computed tomography detection of increased 18F-fluorodeoxyglucose uptake in the cardiac atria of patients with atrial fibrillation. *Int J Cardiol*. 2019;283:171–177. doi: 10.1016/j.ijcard.2018.10.106
44. Heijman J, Guichard JB, Dobrev D, Nattel S. Translational challenges in atrial fibrillation. *Circ Res*. 2018;122:752–773. doi: 10.1161/CIRCRESAHA.117.311081
45. Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, Carter RE, Yao X, Rabinstein AA, Erickson BJ, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. *Lancet*. 2019;394:861–867. doi: 10.1016/S0140-6736(19)31721-0
46. Han L, Askari M, Altman RB, Schmitt SK, Fan J, Bentley JP, Narayan SM, Turakhia MP. Atrial fibrillation burden signature and near-term prediction of stroke: a machine learning analysis. *Circ Cardiovasc Qual Outcomes*. 2019;12:e005595. doi: 10.1161/CIRCOUTCOMES.118.005595
47. Bundy JD, Heckbert SR, Chen LY, Lloyd-Jones DM, Greenland P. Evaluation of risk prediction models of atrial fibrillation (from the Multi-Ethnic Study of Atherosclerosis [MESA]). *Am J Cardiol*. 2020;125:55–62. doi: 10.1016/j.amjcard.2019.09.032
48. Hill NR, Ayoubkhani D, McEwan P, Sugrue DM, Farooqui U, Lister S, Lumley M, Bakhai A, Cohen AT, O'Neill M, et al. Predicting atrial fibrillation in primary care using machine learning. *PLoS One*. 2019;14:e0224582. doi: 10.1371/journal.pone.0224582
49. Goto S, Goto S, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Haas S, Parkhomenko A, Oto A, et al. New AI prediction model using serial PT-INR measurements in AF patients on VKAs: GARFIELD-AF. *Eur Heart J Cardiovasc Pharmacother*. 2019. doi: 10.1093/ehjcvp/pvz076
50. Beam AL, Manrai AK, Ghassemi M. Challenges to the reproducibility of machine learning models in health care. *JAMA*. 2020;323:305–306. doi: 10.1001/jama.2019.20866
51. Matheny ME, Whitcher D, Thadaneys Israni S. Artificial intelligence in health care: a report from the National Academy of Medicine. *JAMA*. 2019;323:509–510. doi: 10.1001/jama.2019.21579
52. Parikh RB, Teeple S, Navathe AS. Addressing bias in artificial intelligence in health care. *JAMA*. 2019;322:2377–2378. doi: 10.1001/jama.2019.18058
53. Charitos EI, Stierle U, Ziegler PD, Baldewig M, Robinson DR, Sievers HH, Hanke T. A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence: insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions. *Circulation*. 2012;126:806–814. doi: 10.1161/CIRCULATIONAHA.112.098079
54. Ng BP, Lai WHS, Chan CKY, Chan SC, Chan LH, Lam KM, Lau HW, Yan CM, Tai LY, Yip KW, et al. Contact-free screening of atrial fibrillation by a smartphone using facial pulsatile photoplethysmographic signals. *J Am Heart Assoc*. 2018;7:e008585. doi: 10.1161/JAHA.118.008585
55. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Baileul C, et al; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. *N Engl J Med*. 2012;366:120–129. doi: 10.1056/NEJMoa1105575
56. O'Sullivan JW, Grigg S, Crawford W, Turakhia MP, Perez M, Ingelsson E, Wheeler MT, Ioannidis JPA, Ashley EA. Accuracy of smartphone camera applications for detecting atrial fibrillation: a systematic review and meta-analysis. *JAMA Netw Open*. 2020;3:e202064. doi: 10.1001/jamanetworkopen.2020.2064



57. Gorenek B, Bax J, Boriani G, Chen SA, Dagres N, Glotzer TV, Healey JS, Israel CW, Kudaiberdieva G, Levin LÅ, et al; ESC Scientific Document Group. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management: an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). *Europace*. 2017;19:1556–1578. doi: 10.1093/europace/eux163
58. Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS. Management of atrial high-rate episodes detected by cardiac implanted electronic devices. *Nat Rev Cardiol*. 2017;14:701–714. doi: 10.1038/nrcardio.2017.94
59. Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. *Am Heart J*. 2017;190:12–18. doi: 10.1016/j.ahj.2017.04.015
60. Healey JS, Wong J. Wearable and implantable diagnostic monitors in early assessment of atrial tachyarrhythmia burden. *Europace*. 2019;21:377–382. doi: 10.1093/europace/euy246
61. Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser SH, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. *Am Heart J*. 2017;189:137–145. doi: 10.1016/j.ahj.2017.04.008
62. Diederichsen SZ, Haugan KJ, Køber L, Højberg S, Brandes A, Kronborg C, Graff C, Holst AG, Nielsen JB, Krieger D, et al. Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): rationale and design of a large randomized controlled trial. *Am Heart J*. 2017;187:122–132. doi: 10.1016/j.ahj.2017.02.017
63. Noseworthy PA, Kaufman ES, Chen LY, Chung MK, Elkind MSV, Joglar JA, Leal MA, McCabe PJ, Pokorney SD, Yao X; American Heart Association Council on Clinical Cardiology Electrophysiology and Arrhythmias Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Sub-clinical and device-detected atrial fibrillation: pondering the knowledge gap: a scientific statement from the American Heart Association. *Circulation*. 2019;140:e944–e963. doi: 10.1161/CIR.0000000000000740
64. Wilson JM, Jungner G. *Principles and Practice of Screening for Disease*. 1968;34. World Health Organization Public Health Paper.
65. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991;22:983–988. doi: 10.1161/01.str.22.8.983
66. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. *Circulation*. 2019;139:e56–e528. doi: 10.1161/CIR.0000000000000659
67. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*. 2014;383:955–962. doi: 10.1016/S0140-6736(13)62343-0
68. Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani H, et al; NHFA CSANZ Atrial Fibrillation Guideline Working Group. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. *Heart Lung Circ*. 2018;27:1209–1266. doi: 10.1016/j.hlc.2018.06.1043
69. Bumgarner JM, Lambert CT, Hussein AA, Cantillon DJ, Baranowski B, Wolski K, Lindsay BD, Wazni OM, Tarakji KG. Smartwatch algorithm for automated detection of atrial fibrillation. *J Am Coll Cardiol*. 2018;71:2381–2388. doi: 10.1016/j.jacc.2018.03.003
70. Turakhia MP, Desai M, Hedlin H, Rajmane A, Talati N, Ferris T, Desai S, Nag D, Patel M, Kowey P, et al. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study. *Am Heart J*. 2019;207:66–75. doi: 10.1016/j.ahj.2018.09.002
71. Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, Hofman C, Houben RP. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. *Europace*. 2014;16:1291–1295. doi: 10.1093/europace/euu057
72. Orchard J, Lowres N, Freedman SB, Ladak L, Lee W, Zwar N, Peiris D, Kamaladasa Y, Li J, Neubeck L. Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): A feasibility study. *Eur J Prev Cardiol*. 2016;23(suppl):13–20. doi: 10.1177/2047487316670255
73. Halcox JPI, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, Gravenor MB. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the RE-HEARSE-AF study. *Circulation*. 2017;136:1784–1794. doi: 10.1161/CIRCULATIONAHA.117.030583
74. Piccini JP, Hammill BG, Sinner MF, Hernandez AF, Walkey AJ, Benjamin EJ, Curtis LH, Heckbert SR. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. *Eur Heart J*. 2014;35:250–256. doi: 10.1093/eurheartj/ehd483
75. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. *Ann Intern Med*. 2013;158:338–346. doi: 10.7326/0003-4819-158-5-201303050-00007
76. Saglietto A, Matta M, Gaita F, Jacobs V, Bunch TJ, Anselmino M. Stroke-independent contribution of atrial fibrillation to dementia: a meta-analysis. *Open Heart*. 2019;6:e000984. doi: 10.1136/openhrt-2018-000984
77. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ*. 2016;354:i4482. doi: 10.1136/bmj.i4482
78. Bekwelem W, Connolly SJ, Halperin JL, Adabag S, Duval S, Chrolavicius S, Pogue J, Ezekowitz MD, Eikelboom JW, Wallentin LG, et al. Extracranial systemic embolic events in patients with nonvalvular atrial fibrillation: incidence, risk factors, and outcomes. *Circulation*. 2015;132:796–803. doi: 10.1161/CIRCULATIONAHA.114.013243
79. Lutsey PL, Norby FL, Alonso A, Cushman M, Chen LY, Michos ED, Folsom AR. Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the Atherosclerosis Risk in Communities Study. *J Thromb Haemost*. 2018;16:670–679. doi: 10.1111/jth.13974
80. Zhang L, Gallagher R, Neubeck L. Health-related quality of life in atrial fibrillation patients over 65 years: a review. *Eur J Prev Cardiol*. 2015;22:987–1002. doi: 10.1177/2047487314538855
81. Rienstra M, Lyass A, Murabito JM, Magnani JW, Lubitz SA, Massaro JM, Ellinor PT, Benjamin EJ. Reciprocal relations between physical disability, subjective health, and atrial fibrillation: the Framingham Heart Study. *Am Heart J*. 2013;166:171–178. doi: 10.1016/j.ahj.2013.02.025
82. Dieleman JL, Cao J, Chapin A, Chen C, Li Z, Liu A, Horst C, Kaldjian A, Matyas T, Scott KW, et al. US health care spending by payer and health condition, 1996–2016. *JAMA*. 2020;323:863–884. doi: 10.1001/jama.2020.0734
83. Nisar MU, Munir MB, Sharbaugh MS, Thoma FW, Althouse AD, Saba S. Trends in atrial fibrillation hospitalizations in the United States: a report using data from the National Hospital Discharge Survey. *Indian Pacing Electrophysiol J*. 2018;18:6–12. doi: 10.1016/j.ipej.2017.07.010
84. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. *Stroke*. 2014;45:520–526. doi: 10.1161/STROKEAHA.113.003433
85. Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol*. 2015;14:377–387. doi: 10.1016/S1474-4422(15)70027-X
86. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, et al; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med*. 2014;370:2478–2486. doi: 10.1056/NEJMoa1313600
87. Vingerhoets F, Bogousslavsky J, Regli F, Van Melle G. Atrial fibrillation after acute stroke. *Stroke*. 1993;24:26–30. doi: 10.1161/01.str.24.1.26
88. Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. *Stroke*. 2016;47:895–900. doi: 10.1161/STROKEAHA.115.012004
89. Park YS, Chung PW, Kim YB, Moon HS, Suh BC, Yoon WT, Yoon KJ, Lee YT, Won YS, Park KY. Small deep infarction in patients with atrial fibrillation: evidence of lacunar pathogenesis. *Cerebrovasc Dis*. 2013;36:205–210. doi: 10.1159/000353736
90. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O'Donnell M, Laupacis A, Côté R, et al; EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med*. 2014;370:2467–2477. doi: 10.1056/NEJMoa1311376

91. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, Cronin L, Cotton D, Grauer C, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. *N Engl J Med*. 2019;380:1906–1917. doi: 10.1056/NEJMoa1813959
92. Hart RG, Sharma M, Mundt H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, et al; NAVIGATE ESUS Investigators. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. *N Engl J Med*. 2018;378:2191–2201. doi: 10.1056/NEJMoa1802686
93. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M, Weimar C, Köhrmann M, Wachter R, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. *Stroke*. 2013;44:3357–3364. doi: 10.1161/STROKEAHA.113.001884
94. Rizo T, Güntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, Reinhardt R, Hepp T, Kirchhof P, Aleynichenko E, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. *Stroke*. 2012;43:2689–2694. doi: 10.1161/STROKEAHA.112.654954
95. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D'Avila A, Dobrev D, et al. EHRA/HRS/APHS/SOLACE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. *Heart Rhythm*. 2017;14:e3–e40. doi: 10.1016/j.hrthm.2016.05.028
96. Poli S, Diedler J, Härtig F, Götz N, Bauer A, Sachse T, Müller K, Müller I, Stimpfle F, Duckheim M, et al. Insertable cardiac monitors after cryptogenic stroke—a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. *Eur J Neurol*. 2016;23:375–381. doi: 10.1111/ene.12843
97. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundt H, Epstein AE, Haeusler KG, Mikulik R, Kasner SE, Toni D, et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial. *JAMA Neurol*. 2019;76:764–773. doi: 10.1001/jamaneurol.2019.0617
98. Lombard V, Antolin-Fontes A, Bustamante A, Giralt D, Rost NS, Furie K, Shibasaki K, Biterker M, Castillo J, Rodríguez-Yáñez M, et al. B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis. *Stroke*. 2015;46:1187–1195. doi: 10.1161/STROKEAHA.114.008311
99. Lubitz SA, Yin X, Lin HJ, Kolek M, Smith JG, Trompet S, Rienstra M, Rost NS, Teixeira PL, Almgren P, et al; AFGen Consortium. Genetic risk prediction of atrial fibrillation. *Circulation*. 2017;135:1311–1320. doi: 10.1161/CIRCULATIONAHA.116.024143
100. Joubert J, Reid C, Barton D, Cumming T, McLean A, Joubert L, Barlow J, Ames D, Davis S. Integrated care improves risk-factor modification after stroke: initial results of the Integrated Care for the Reduction of Secondary Stroke model. *J Neurol Neurosurg Psychiatry*. 2009;80:279–284. doi: 10.1136/jnnp.2008.148122
101. Orchard J, Neubeck L, Freedman B, Li J, Webster R, Zwar N, Gallagher R, Ferguson C, Lowres N. eHealth tools to provide structured assistance for atrial fibrillation screening, management, and guideline-recommended therapy in metropolitan general practice: the AF - SMART Study. *J Am Heart Assoc*. 2019;8:e010959. doi: 10.1161/JAHA.118.010959
102. Orchard J, Li J, Freedman B, Webster R, Salkeld G, Hespe C, Gallagher R, Patel A, Kamel B, Neubeck L, et al. Atrial fibrillation screen, management, and guideline-recommended therapy in the rural primary care setting: a cross-sectional study and cost-effectiveness analysis of eHealth tools to support all stages of screening. *J Am Heart Assoc*. 2020:e017080. doi: 10.1161/JAHA.120.017080
103. Rooney MR, Soliman EZ, Lutsey PL, Norby FL, Loehr LR, Mosley TH, Zhang M, Gottesman RF, Coresh J, Folsom AR, et al. Prevalence and characteristics of subclinical atrial fibrillation in a community-dwelling elderly population: the ARIC study. *Circ Arrhythm Electrophysiol*. 2019;12:e007390. doi: 10.1161/CIRCEP.119.007390
104. McIntyre WF, Yong JHE, Sandhu RK, Gladstone DJ, Simek K, Liu YY, Quinn FR, Tytus R, Zizzo D, Henein S, et al. Prevalence of undiagnosed atrial fibrillation in elderly individuals and potential cost-effectiveness of non-invasive ambulatory electrocardiographic screening: the ASSERT-III study. *J Electrocardiol*. 2020;58:56–60. doi: 10.1016/j.jelectrocard.2019.11.040
105. Proietti M, Mairesse GH, Goethals P, Scavee C, Vijgen J, Blankoff I, Vandekerckhove Y, Lip GY, Belgian Heart Rhythm Week Investigators. A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. *Europace*. 2016;18:1779–1786. doi: 10.1093/europace/euw069
106. Kaasenbrood F, Hollander M, Rutten FH, Gerhards LJ, Hoes AW, Tieleman RG. Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. *Europace*. 2016;18:1514–1520. doi: 10.1093/europace/euv426
107. Jacobs MS, Kaasenbrood F, Postma MJ, van Hulst M, Tieleman RG. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. *Europace*. 2018;20:12–18. doi: 10.1093/europace/euw285
108. Chan NY, Choy CC, Chan CK, Siu CW. Effectiveness of a nongovernmental organization-led large-scale community atrial fibrillation screening program using the smartphone electrocardiogram: an observational cohort study. *Heart Rhythm*. 2018;15:1306–1311. doi: 10.1016/j.hrthm.2018.06.006
109. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. *J Am Coll Cardiol*. 2019;74:2365–2375. doi: 10.1016/j.jacc.2019.08.019
110. Diederichsen SZ, Haugan KJ, Brandes A, Lannig MB, Graff C, Krieger D, Kronborg C, Holst AG, Køber L, Højberg S, et al. Natural history of sub-clinical atrial fibrillation detected by implanted loop recorders. *J Am Coll Cardiol*. 2019;74:2771–2781. doi: 10.1016/j.jacc.2019.09.050
111. Diederichsen SZ, Haugan KJ, Brandes A, Graff C, Krieger D, Kronborg C, Holst AG, Nielsen JB, Køber L, Højberg S, et al. Incidence and predictors of atrial fibrillation episodes as detected by implantable loop recorder in patients at risk: from the LOOP study. *Am Heart J*. 2020;219:117–127. doi: 10.1016/j.ahj.2019.09.009
112. Diederichsen SZ, Haugan KJ, Kronborg C, Graff C, Højberg S, Køber L, Krieger D, Holst AG, Nielsen JB, Brandes A, et al. Comprehensive evaluation of rhythm monitoring strategies in screening for atrial fibrillation: insights from patients at risk monitored long term with an implantable loop recorder. *Circulation*. 2020;141:1510–1522. doi: 10.1161/CIRCULATIONAHA.119.044407
113. Steinhubl SR, Waalen J, Edwards AM, Arinello LM, Mehta RR, Ebner GS, Carter C, Baca-Motes K, Felicione E, Sarich T, et al. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. *JAMA*. 2018;320:146–155. doi: 10.1001/jama.2018.8102
114. Smyth B, Marsden P, Corcoran R, Walsh R, Brennan C, McSharry K, Clarke J, Kelly PJ, Harbison J. Opportunistic screening for atrial fibrillation in a rural area. *QJM*. 2016;109:539–543. doi: 10.1093/qjmed/hcw011
115. Quinn FR, Gladstone DJ, Ivers NM, Sandhu RK, Dolovich L, Ling A, Nakamya J, Ramasundarahettige C, Frydrych PA, Henein S, et al. Diagnostic accuracy and yield of screening tests for atrial fibrillation in the family practice setting: a multicentre cohort study. *CMAJ Open*. 2018;6:E308–E315. doi: 10.9778/cmajo.20180001
116. Tarride JE, Quinn FR, Blackhouse G, Sandhu RK, Burke N, Gladstone DJ, Ivers NM, Dolovich L, Thornton A, Nakamya J, et al. Is screening for atrial fibrillation in Canadian family practices cost-effective in patients 65 years and older? *Can J Cardiol*. 2018;34:1522–1525. doi: 10.1016/j.cjca.2018.05.016
117. Tarride JE, Dolovich L, Blackhouse G, Guertin JR, Burke N, Manja V, Grinvalds A, Lim T, Healey JS, Sandhu RK. Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. *CMAJ Open*. 2017;5:E653–E661. doi: 10.9778/cmajo.20170042
118. Sandhu RK, Dolovich L, Deif B, Barake W, Agarwal G, Grinvalds A, Lim T, Quinn FR, Gladstone D, Conen D, et al. High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. *Open Heart*. 2016;3:e000515. doi: 10.1136/openhrt-2016-000515
119. Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Stepwise mass screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). *Europace*. 2013;15:135–40. doi: 10.1093/europace/eus217
120. Uittenbogaart SB, Verbiest-van Gorp N, Erkens PM, Lucassen WA, Knottnerus JA, Winkens B, van Weert HC, Stoffers HE. Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial. *Trials*. 2015;16:478. doi: 10.1186/s13063-015-1006-5
121. Kemp Gudmundsdottir K, Fredriksson T, Svennberg E, Al-Khalili F, Friberg L, Frykman V, Hijazi Z, Rosenqvist M, Engdahl J. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. *Europace*. 2020;22:24–32. doi: 10.1093/europace/euz255
122. Schnabel RB, Haeusler KG, Healey JS, Freedman B, Boriani G, Brachmann J, Brandes A, Bustamante A, Casadei B, Crijns HJGM, et al. Searching for atrial fibrillation poststroke: a white paper of the AF-SCREEN international collaboration. *Circulation*. 2019;140:1834–1850. doi: 10.1161/CIRCULATIONAHA.119.040267